

Bibliografia

- 1) Stokin GB, Krell-Roesch J, Petersen RC, et al. Mild neurocognitive disorder: an old wine in a new bottle. *Harv Rev Psychiatry* 2015; 23:368-376. <https://doi.org/10.1097/HRP.0000000000000084>
- 2) Pirani A, Antonelli Incalzi R, Biggio G, et al. L'approccio al paziente con declino cognitivo lieve: risultati di un'indagine in Medicina Generale. *Rivista SIMG* 2020;27:9-18.
- 3) Amenta F, Parnetti L, Gallai V, et al. Treatment of cognitive dysfunction associated with Alzheimer's disease with cholinergic precursors. Ineffective treatments or inappropriate approaches? *Mech Ageing Dev* 2001;122:2025-2040. [https://doi.org/10.1016/s0047-6374\(01\)00310-4](https://doi.org/10.1016/s0047-6374(01)00310-4)
- 4) Kansakar U, Trimarco V, Mone P, et al. Choline supplements: an update. *Front Endocrinol* 2023;14:1148166. <https://doi.org/10.3389/fendo.2023.1148166>
- 5) Alvarez-Sabín J, Santamarina E, Maisterra O, et al. Long-term treatment with citicolina prevents cognitive decline and predicts a better quality of life after a first ischemic stroke. *Int J Mol Sci* 2016;17:390. <https://doi.org/10.3390/ijms17030390>
- 6) Secades JJ, Gareri P. Citicolina: pharmacological and clinical review, 2022 update. *Rev Neurol* 2022;75:S1-S89. <https://doi.org/10.33588/rn.75s05.2022311>
- 7) Zhang F, Wang S, Gan L, et al. Protective effects and mechanisms of sirtuins in the nervous system. *Prog Neurobiol* 2011;95:373-395. <https://doi.org/10.1016/j.pneurobio.2011.09.001>
- 8) Gareri P, Cotroneo AM, Orsitto G, et al. The CITIMEM study: a pilot study. Optimizing pharmacological treatment in dementia. *Arch Gerontol Geriatr* 2020;89:104073. <https://doi.org/10.1016/j.archger.2020.104073>
- 9) Gareri P, Cotroneo AM, Manfredi VGL. From neuroinflammation to neuroprotection: focus on potential new therapeutic targets in cognitive impairment. *Neurol Neurobiol J* 2020;3:1- 4. <https://doi.org/10.31487/j.NNB.2020.02.10>
- 10) Dash UC, Bhol NK, Swain SK, et al. Oxidative stress and inflammation in the pathogenesis of neurological disorders: mechanisms and implications. *Acta Pharm Sin B* 2025;15:15- 34. <https://doi.org/10.1016/j.apsb.2024.10.004>
- 11) Ferreira-Vieira TH, Guimaraes IM, Silva FR, et al. Alzheimer's disease: targeting the cholinergic system. *Curr Neuropharmacol* 2016;14:101-115. <https://doi.org/10.2174/1570159x13666150716165726>
- 12) Chaves-Coira I, García-Magro N, Zegarra-Valdivia J, et al. Cognitive deficits in aging related to changes in basal forebrain neuronal activity. *Cells* 2023;12:1477. <https://doi.org/10.3390/cells12111477>
- 13) Martynov MY, Gusev EI. Current knowledge on the neuroprotective and neuroregenerative properties of citicolina in acute ischemic stroke. *J Exp Pharmacol* 2015;7:17-28. <https://doi.org/10.2147/JEP.S63544>
- 14) Fioravanti M, Yanagi M. Cytidinediphosphocholine (CDP-choline) for cognitive and behavioural disturbances associated with chronic cerebral disorders in the elderly. *Cochrane Database Syst Rev* 2005;(2):CD000269. <https://doi.org/10.1002/14651858.CD000269.pub3>
- 15) Putignano S, Gareri P, Castagna A, et al. Retrospective and observational study to assess the efficacy of citicolina in elderly patients suffering from stupor related to complex geriatric syndrome. *Clin Interv Aging* 2012;7:113-118. <https://doi.org/10.2147/CIA.S29366>
- 16) Gareri P, Castagna A, Cotroneo AM, et al. The role of citicolina in cognitive impairment: pharmacological characteristics, possible advantages, and doubts for an old drug with new perspectives. *Clin Interv Aging* 2015;10:1421-1429. <https://doi.org/10.2147/CIA.S87886>